Treatment Action Group (TAG) recently released its Spring 2013 issue of tagline, which contains three articles about TB research that might be of interest to you– 1) on rifapentine research and access, 2) on adaptive clinical trial designs, and 3) on pediatric drug development needs.
To commemorate World TB Day 2013, The Lancet Infectious Diseases publishes a Series of papers on tuberculosis, a disease that has long plagued human beings and was declared a global emergency in 1993 by WHO.
World TB Day is celebrated on March 24 and there is a lot going on during this week and next to highlight the continued problem of TB in the world and the solutions to address the problem. Included is a list of publications, news items, events, and links related to TB and World TB Day 2013.
The results of the first TB vaccine efficacy trial in over 90 years was released today showing that the vaccine candidate MVA85A when given as a booster did not provide added protection to infants who had already received BCG. The trial adds scientific value to the field and enhances the field’s understanding and ability in conducting large-scale TB vaccine trials. Additional links to TB R&D news are included.
The week of November 12th was exciting with the 43rd Union World Conference, the WGND Annual Meeting (will be posting presentations soon), and the Stop TB Coordinating Board Meeting. Included are some news highlights and a listing of webcasts of interesting and presentations relevant for TB drug development and research.
The WHO released the Global Tuberculosis Report 2012 today. The main highlights and additional coverage are included.
The Stakeholder and Community Engagement Workgroup of the Critical Path to TB Drug Regimens initiative launches guidelines that will facilitate the involvement of communities and participants in the conduct of TB drug trials.
This week we highlight a study showing promising results that providing high dose vitamin D supplements along with antibiotics could improve treatment outcomes for TB patients. The abstract and additional news coverage are included, as well as, links to other TB R&D news.
The 2012 Millennium Development Report was just released highlighting progress made to date. Great strides have been made in HIV and TB from the year 1990 (see below). The Global Plan to Stop TB issued by the Stop TB Partnership is set within the context of the Millennium Development Goals (MDGs).
Yesterday, efficacy data from the first novel regimen trial (NC001) were published in the Lancet. The results found that the regimen containing PA-824, moxifloxacin, and pyrazinamide, could kill more than 99 percent of patients’ TB bacteria within two weeks and could be more effective than existing treatments. Link to article, press release, and related video are included. Additional links to TB R&D news are also included.